MedTrace Logo

A Controlled Study of Improved Javelin Side Recumbent Position and Conventional Postural Placement

NCT05551442 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-09-22

No results posted yet for this study

Summary

The Da Vinci surgical robot Xi system assisted laparoscopic pyeloureteroplasty uses the improved javelin side lying position, which can alleviate the unsafe factors of falling from the bed caused by the conventional posture, shorten the time of placing the posture5, prevent the possible pressure injuries and intraoperative complications caused by the conventional posture surgery, and the operation is more simple and convenient. The mechanical arm of the Da Vinci robot will not have the potential risk factors of crushing the head, face and trunk of the patient during the entire operation process, It is safe and reliable, making the whole process of positioning convenient and time-saving. It can not only improve the connection efficiency of each operation, but also ease the work intensity of nurses and reduce the incidence of robot secondary berths. Operator satisfaction. It is safe and reliable to achieve good results, improve the operation safety, effectively avoid intraoperative and postoperative complications, and ensure the operation safety of patients, which is worth promoting.

Conditions

  • Nurse-Patient Relations

Interventions

PROCEDURE

To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.

The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.

DEVICE

To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform

To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform

Sponsors & Collaborators

  • Guiyang Maternal and Child Health Care Hospital

    lead OTHER

Principal Investigators

  • Jing P Liu, doctorat · Guizhou Provincial People's Hospital

Eligibility

Min Age
2 Months
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-12
Primary Completion
2022-01-09
Completion
2022-09-07
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05551442 on ClinicalTrials.gov